Doing now what patients need next
:quality(90)/)
We are Roche
A healthier future. It’s what drives us to innovate.
To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.
Creating a world where we all have more time with the people we love.
That’s what makes us Roche.
In the spotlight
:quality(90)/)
:quality(90)/)
For Investors
:quality(90)/)
:quality(90)/)
:quality(90)/)
Identifying high-risk patients
We will prevent diseases by identifying high-risk patients early to enable timely use of medicines.
:quality(90)/)
Halting disease progression
We will stop diseases by accurately diagnosing and stratifying patients to halt disease progression through targeted medicines.
:quality(90)/)
Restoring health through medicines
We will cure diseases by identifying the cause of disease in order to restore health through curative medicines.
:quality(90)/)
:quality(90)/)
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reducing disability progression in PPMS
:quality(90)/)
Roche Accessibility Statement
At Roche, we are committed to ensuring that our websites and digital resources are accessible to all users.
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)